Loading...
Header Logo
Keywords
Last Name
Institution

ADRIAN P GEE

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
DivisionPediatrics-Hem/Onc Cell & Gene The
AddressOne Baylor Plaza
Houston TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Medicine
    DivisionMedicine-Hematology & Oncology


    Collapse Biography 
    Collapse awards and honors
    2017Career Achievement Award, International Soc. of Cellular Therapy

    Collapse Research 
    Collapse research activities and funding
    268201000007C-1-0-1     (GEE, ADRIAN PHILIP)Jan 15, 2010 - Jan 14, 2015
    NIH/NHLBI
    PACT
    Role: Principal Investigator

    268201000007C-2-0-1     (GEE, ADRIAN PHILIP)Jan 15, 2010 - Jan 14, 2015
    NIH/NHLBI
    PACT
    Role: Principal Investigator

    268201000007C-5-0-1     (GEE, ADRIAN PHILIP)Jan 15, 2010 - Jan 14, 2015
    NIH/NHLBI
    PACT
    Role: Principal Investigator

    268201000007C-6-0-1     (GEE, ADRIAN PHILIP)Jan 15, 2010 - Jan 14, 2015
    NIH/NHLBI
    PACT
    Role: Principal Investigator

    R44HL132348     (WILSON, JOHN)Jun 15, 2017 - Mar 31, 2020
    NIH/NHLBI
    Path to Commercialization of the first ?off the shelf? T cell product
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 Nov 29; 132(22):2351-2361. PMID: 30262660.
      View in: PubMed
    2. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 Dec 05; 26(12):2727-2737. PMID: 30309819.
      View in: PubMed
    3. Bolli R, Hare JM, Henry TD, Lenneman CG, March KL, Miller K, Pepine CJ, Perin EC, Traverse JH, Willerson JT, Yang PC, Gee AP, Lima JA, Moyé L, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Ebert RF, Simari RD. Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. Am Heart J. 2018 Jul; 201:54-62. PMID: 29910056.
      View in: PubMed
    4. Gee AP. GMP CAR-T cell production. Best Pract Res Clin Haematol. 2018 06; 31(2):126-134. PMID: 29909913.
      View in: PubMed
    5. Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 Apr 10; 36(11):1128-1139. PMID: 29315015.
      View in: PubMed
    6. Gee AP. Regulation of Regenerative Medicine Products. Adv Exp Med Biol. 2018; 1098:189-198. PMID: 30238372.
      View in: PubMed
    7. Lyon D, Lapteva N, Gee AP. Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther. 2018 01 03; 26(1):6-7. PMID: 29301109.
      View in: PubMed
    8. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Chugh A, Yang PC, Zhao DXM, Ellis SG, Forder JR, Perin EC, Penn MS, Hatzopoulos AK, Chambers JC, Baran KW, Raveendran G, Gee AP, Taylor DA, Moyé L, Ebert RF, Simari RD. TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. Circ Res. 2018 Feb 02; 122(3):479-488. PMID: 29208679.
      View in: PubMed
    9. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471. PMID: 28805662.
      View in: PubMed
    10. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557. PMID: 28783452.
      View in: PubMed
    11. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101. PMID: 28426845.
      View in: PubMed
    12. Szoor A, Vaidya A, Velasquez MP, Mei Z, Galvan DL, Torres D, Gee A, Heczey A, Gottschalk S. T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics. 2017 Sep 15; 6:69-79. PMID: 28856237.
      View in: PubMed
    13. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224. PMID: 28602436.
      View in: PubMed
    14. Liu S, de Castro LF, Jin P, Civini S, Ren J, Reems JA, Cancelas J, Nayak R, Shaw G, O'Brien T, McKenna DH, Armant M, Silberstein L, Gee AP, Hei DJ, Hematti P, Kuznetsov SA, Robey PG, Stroncek DF. Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple Centers. Sci Rep. 2017 Apr 27; 7:46731. PMID: 28447618.
      View in: PubMed
    15. Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC, Leeper NJ, Dalman RL, Alexander J, Henry TD, Traverse JH, Pepine CJ, Anderson RD, Berceli S, Willerson JT, Muthupillai R, Gahremanpour A, Raveendran G, Velasquez O, Hare JM, Hernandez Schulman I, Kasi VS, Hiatt WR, Ambale-Venkatesh B, Lima JA, Taylor DA, Resende M, Gee AP, Durett AG, Bloom J, Richman S, G'Sell P, Williams S, Khan F, Gyang Ross E, Santoso MR, Goldman J, Leach D, Handberg E, Cheong B, Piece N, DiFede D, Bruhn-Ding B, Caldwell E, Bettencourt J, Lai D, Piller L, Simpson L, Cohen M, Sayre SL, Vojvodic RW, Moyé L, Ebert RF, Simari RD, Hirsch AT. Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). Circulation. 2017 Apr 11; 135(15):1417-1428. PMID: 28209728.
      View in: PubMed
    16. Parsha K, Mir O, Satani N, Yang B, Guerrero W, Mei Z, Cai C, Chen PR, Gee A, Hanley PJ, Aronowski J, Savitz SI. Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants. Cytotherapy. 2017 01; 19(1):36-46. PMID: 27856228.
      View in: PubMed
    17. Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96. PMID: 27270177.
      View in: PubMed
    18. Lapteva N, Parihar R, Rollins LA, Gee AP, Rooney CM. Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202. PMID: 27177667.
      View in: PubMed
    19. Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016 Feb; 18(2):151-9. PMID: 26724220; PMCID: PMC4745114.
    20. Salem B, Miner S, Hensel NF, Battiwalla M, Keyvanfar K, Stroncek DF, Gee AP, Hanley PJ, Bollard CM, Ito S, Barrett AJ. Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. Cytotherapy. 2015 Dec; 17(12):1675-86. PMID: 26422657.
      View in: PubMed
    21. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13. PMID: 25977584; PMCID: PMC4481597.
    22. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96. PMID: 25800760; PMCID: PMC4429176.
    23. Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer. 2015; 3:5. PMID: 25734008; PMCID: PMC4346112.
    24. Gee AP. Manufacturing genetically modified T cells for clinical trials. Cancer Gene Ther. 2015 Mar; 22(2):67-71. PMID: 25633481.
      View in: PubMed
    25. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285; PMCID: PMC4352951.
    26. Bloom DD, Centanni JM, Bhatia N, Emler CA, Drier D, Leverson GE, McKenna DH, Gee AP, Lindblad R, Hei DJ, Hematti P. A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. Cytotherapy. 2015 Feb; 17(2):140-51. PMID: 25455739.
      View in: PubMed
    27. Gee AP. CD34 measurement: setting standards. Cytotherapy. 2014 Nov; 16(11):1451-1452. PMID: 25287598.
      View in: PubMed
    28. Lindblad RW, Ibenana L, Wagner JE, McKenna DH, Hei DJ, Hematti P, Couture LA, Silberstein LE, Armant M, Rooney CM, Gee AP, Welniak LA, Heath Mondoro T, Wood DA, Styers D. Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program. Transfusion. 2015 Mar; 55(3):674-9. PMID: 25315143; PMCID: PMC4357544.
    29. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83. PMID: 24964991; PMCID: PMC4181611.
    30. Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF. Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev. 2014; 1:14015. PMID: 26015959; PMCID: PMC4362380.
    31. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9. PMID: 24782509; PMCID: PMC4055922.
    32. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905. PMID: 24753538; PMCID: PMC4064331.
    33. Hanley PJ, Mei Z, Durett AG, Cabreira-Hansen Mda G, Cabreira-Harrison Mda G, Klis M, Li W, Zhao Y, Yang B, Parsha K, Mir O, Vahidy F, Bloom D, Rice RB, Hematti P, Savitz SI, Gee AP. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy. 2014 Aug; 16(8):1048-58. PMID: 24726657; PMCID: PMC4087082.
    34. Wood D, Wesselschmidt R, Hematti P, Gee AP, Rooney C, Silberstein L, Armant M, Couture L, Wagner JE, McKenna DH, Hei D, Mondoro TH, Welniak L, Lindblad R. An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy. Clin Transl Sci. 2014 Apr; 7(2):93-9. PMID: 24655892; PMCID: PMC4006308.
    35. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808. PMID: 24344220; PMCID: PMC3940538.
    36. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73. PMID: 24030379; PMCID: PMC3811171.
    37. Gee AP. How to design a cell or gene therapy clinical trial: advice from the FDA. Mol Ther. 2013 Sep; 21(9):1639-40. PMID: 24008615; PMCID: PMC3953992.
    38. Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, Gee AP, Wang RF, Hayes TG. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242. PMID: 23609828; PMCID: PMC4100683.
    39. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23. PMID: 23610374; PMCID: PMC3695359.
    40. Hanley PJ, Mei Z, da Graca Cabreira-Hansen M, Klis M, Li W, Zhao Y, Durett AG, Zheng X, Wang Y, Gee AP, Horwitz EM. Manufacturing mesenchymal stromal cells for phase I clinical trials. Cytotherapy. 2013 Apr; 15(4):416-22. PMID: 23480951.
      View in: PubMed
    41. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012 Dec 12; 308(22):2380-9. PMID: 23129008; PMCID: PMC3652242.
    42. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43. PMID: 22900959.
      View in: PubMed
    43. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012 Apr 25; 307(16):1717-26. PMID: 22447880; PMCID: PMC3600947.
    44. Richman S, Gee AP, McKenna DH, Traverse JH, Henry TD, Fisk D, Pepine CJ, Bloom J, Willerson JT, Prater K, Zhao D, Koç JR, Anwaruddin S, Taylor DA, Cogle CR, Moyé LA, Simari RD, Skarlatos SI. Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study. Transfusion. 2012 Oct; 52(10):2225-33. PMID: 22320233; PMCID: PMC3355200.
    45. Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11. PMID: 22172091.
      View in: PubMed
    46. Zierold C, Carlson MA, Obodo UC, Wise E, Piazza VA, Meeks MW, Vojvodic RW, Baraniuk S, Henry TD, Gee AP, Ellis SG, Moyé LA, Pepine CJ, Cogle CR, Taylor DA. Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. Am Heart J. 2011 Dec; 162(6):973-80. PMID: 22137069; PMCID: PMC3236502.
    47. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011 Nov 16; 306(19):2110-9. PMID: 22084195; PMCID: PMC3600981.
    48. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83. PMID: 22047558; PMCID: PMC3236370.
    49. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6. PMID: 21984804; PMCID: PMC3234664.
    50. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82. PMID: 21933889; PMCID: PMC3865786.
    51. Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM, Gee AP, Gibson J, Laughlin MJ, Lazarus HM, Loren A, Marks DI, Gratwohl A, Eapen M. Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1869-73. PMID: 21771571; PMCID: PMC3217167.
    52. Savitz SI, Misra V, Kasam M, Juneja H, Cox CS, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011 Jul; 70(1):59-69. PMID: 21786299.
      View in: PubMed
    53. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6. PMID: 21540550; PMCID: PMC3083795.
    54. Cox CS, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, Ewing-Cobbs L, Hasan KM, Day MC, Lee D, Jimenez F, Gee A. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery. 2011 Mar; 68(3):588-600. PMID: 21192274.
      View in: PubMed
    55. Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011 May; 13(5):518-22. PMID: 21361747.
      View in: PubMed
    56. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90. PMID: 20948438; PMCID: PMC2964409.
    57. Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, Marsh J, Russell J, Sabloff M, Waller EK, Eapen M. Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1018-24. PMID: 21034842; PMCID: PMC3114180.
    58. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9. PMID: 20429793.
      View in: PubMed
    59. Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy. 2010 Sep; 12(5):684-91. PMID: 20524773.
      View in: PubMed
    60. Whiteside TL, Griffin DL, Stanson J, Gooding W, McKenna D, Sumstad D, Kadidlo D, Gee A, Durett A, Lindblad R, Wood D, Styers D. Shipping of therapeutic somatic cell products. Cytotherapy. 2011 Feb; 13(2):201-13. PMID: 20795760.
      View in: PubMed
    61. Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD. Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am Heart J. 2010 Aug; 160(2):215-23. PMID: 20691824; PMCID: PMC2921924.
    62. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010 Jul; 11(7):653-60. PMID: 20558104; PMCID: PMC3163510.
    63. Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R, Loper K, McKenna D, Rooney C, Sabatino M, Wagner E, Whiteside T, Wood D, Heath-Mondoro T. Developments in clinical cell therapy. Cytotherapy. 2010 May; 12(3):425-8. PMID: 20078383.
      View in: PubMed
    64. El Khoury R, Misra V, Sharma S, Cox CS, Walker P, Grotta JC, Gee A, Suzuki S, Savitz SI. The effect of transcatheter injections on cell viability and cytokine release of mononuclear cells. AJNR Am J Neuroradiol. 2010 Sep; 31(8):1488-92. PMID: 20395386.
      View in: PubMed
    65. McKenna DH, Adams S, Sumstad D, Sumstad T, Kadidlo D, Gee AP, Durett A, Griffin D, Donnenberg A, Amrani D, Livingston D, Lindblad R, Wood D, Styers D. CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine. Cytotherapy. 2010 Apr; 12(2):170-7. PMID: 20078385.
      View in: PubMed
    66. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703. PMID: 20110422; PMCID: PMC2852368.
    67. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010; 37(4):412-20. PMID: 20844613.
      View in: PubMed
    68. Collins NH, Gee AP, Durett AG, Kan F, Zhang MJ, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJ. The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. Biol Blood Marrow Transplant. 2010 Feb; 16(2):253-62. PMID: 19822219; PMCID: PMC2952392.
    69. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92. PMID: 19700662.
      View in: PubMed
    70. Traverse JH, Henry TD, Vaughan DE, Vaughn DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD. Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J. 2009 Sep; 158(3):356-63. PMID: 19699857; PMCID: PMC2784639.
    71. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67. PMID: 19443656; PMCID: PMC2738578.
    72. Lazarus HM, Kan F, Tarima S, Champlin RE, Confer DL, Frey N, Gee AP, Wagner JE, Horowitz MM, Eapen M. Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. Biol Blood Marrow Transplant. 2009 May; 15(5):589-96. PMID: 19361751; PMCID: PMC2688780.
    73. Harting MT, Cox CS, Day MC, Walker P, Gee A, Brenneman MM, Grotta JC, Savitz SI. Bone marrow-derived mononuclear cell populations in pediatric and adult patients. Cytotherapy. 2009; 11(4):480-4. PMID: 19462318.
      View in: PubMed
    74. Reed W, Noga SJ, Gee AP, Rooney CM, Wagner JE, McCullough J, McKenna DH, Whiteside TL, Donnenberg AD, Baker AK, Lindblad RW, Wagner EL, Mondoro TH. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion. 2009 Apr; 49(4):786-96. PMID: 19170985.
      View in: PubMed
    75. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70. PMID: 18978797; PMCID: PMC2749734.
    76. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50. PMID: 18971421; PMCID: PMC2656271.
    77. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008 May; 41(9):771-8. PMID: 18209724; PMCID: PMC4086223.
    78. Harting MT, Baumgartner JE, Worth LL, Ewing-Cobbs L, Gee AP, Day MC, Cox CS. Cell therapies for traumatic brain injury. Neurosurg Focus. 2008; 24(3-4):E18. PMID: 18341394; PMCID: PMC3721356.
    79. Gee AP, Sumstad D, Stanson J, Watson P, Proctor J, Kadidlo D, Koch E, Sprague J, Wood D, Styers D, McKenna D, Gallelli J, Griffin D, Read EJ, Parish B, Lindblad R. A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. Cytotherapy. 2008; 10(4):427-35. PMID: 18574775.
      View in: PubMed
    80. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54. PMID: 17942545; PMCID: PMC2224388.
    81. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007 Dec; 13(12):1461-8. PMID: 18022576; PMCID: PMC2267869.
    82. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Terminology and labeling of cellular products: 1. Standards. Bone Marrow Transplant. 2007 Dec; 40(11):1075-83. PMID: 17906708.
      View in: PubMed
    83. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Terminology and labeling of cellular products-2: Implementation plan. Bone Marrow Transplant. 2007 Dec; 40(11):1085-90. PMID: 17906707.
      View in: PubMed
    84. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45. PMID: 17609424; PMCID: PMC2018666.
    85. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Standards for the terminology and labeling of cellular therapy products. Transfusion. 2007 Jul; 47(7):1319-27. PMID: 17581170.
      View in: PubMed
    86. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. ISBT 128 implementation plan for cellular therapy products. Transfusion. 2007 Jul; 47(7):1312-8. PMID: 17581169.
      View in: PubMed
    87. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Standards for the terminology and labeling of cellular therapy products. J Clin Apher. 2007; 22(5):249-57. PMID: 17823945.
      View in: PubMed
    88. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. ISBT 128 implementation plan for cellular therapy products. J Clin Apher. 2007; 22(5):258-64. PMID: 17823946.
      View in: PubMed
    89. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, Gee AP, Scott JD, Savoldo B. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94. PMID: 17100717.
      View in: PubMed
    90. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6. PMID: 16998485.
      View in: PubMed
    91. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9. PMID: 16835376; PMCID: PMC1895521.
    92. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808. PMID: 16741253; PMCID: PMC1895537.
    93. Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93. PMID: 16824159.
      View in: PubMed
    94. Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7. PMID: 16507214.
      View in: PubMed
    95. Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, Gee AP, Heslop HE, Rooney CM. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15. PMID: 16461793.
      View in: PubMed
    96. Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41. PMID: 16249392; PMCID: PMC1895421.
    97. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23. PMID: 16203783.
      View in: PubMed
    98. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8. PMID: 16095501.
      View in: PubMed
    99. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33. PMID: 15611290; PMCID: PMC2211993.
    100. McCullough J, Wagner J, Key N, Gee A, Rooney C, Whiteside T, Donnenberg A, Lindblad R. Production assistance for cellular therapies. Transfusion. 2004 Dec; 44(12):1793-5. PMID: 15584997.
      View in: PubMed
    101. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 01; 105(5):1898-904. PMID: 15542583.
      View in: PubMed
    102. Rousseau RF, Gee AP. [Impact of regulations on translational research in cell and gene therapy: the American experience]. Bull Cancer. 2004 Mar; 91(3):239-47. PMID: 15171048.
      View in: PubMed
    103. Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Rhee Fv Fv, DeRienzo S, O'Neal W, Lamb L, Henslee-Downey PJ. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant. 2004 Feb; 33(4):389-96. PMID: 14716338.
      View in: PubMed
    104. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81. PMID: 14751931.
      View in: PubMed
    105. Gee AP. Regulatory issues in cellular therapies. Expert Opin Biol Ther. 2003 Jul; 3(4):537-40. PMID: 12831359.
      View in: PubMed
    106. Grilley BJ, Gee AP. Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. Cytotherapy. 2003; 5(3):197-207. PMID: 12850787.
      View in: PubMed
    107. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26. PMID: 12406881.
      View in: PubMed
    108. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66. PMID: 12393655.
      View in: PubMed
    109. Gee AP. The impact of regulatory policy on the development of somatic cell therapies in the United States. Transpl Immunol. 2002 May; 9(2-4):295-300. PMID: 12180844.
      View in: PubMed
    110. Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, Rooney CM. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18. PMID: 11777989.
      View in: PubMed
    111. Gee AP. What a cell-processing laboratory can and can't do for cellular therapy. Cytotherapy. 2002; 4(5):447-8. PMID: 12473221.
      View in: PubMed
    112. Gee AP, Durett AG. Cell sorting for therapeutic applications - points to consider. Cytotherapy. 2002; 4(1):91-2. PMID: 11953049.
      View in: PubMed
    113. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33. PMID: 11785836.
      View in: PubMed
    114. Ye Z, Haley S, Gee AP, Henslee-Downey PJ, Lamb LS. In vitro interactions between gamma deltaT cells, DC, and CD4+ T cells; implications for the immunotherapy of leukemia. Cytotherapy. 2002; 4(3):293-304. PMID: 12194726.
      View in: PubMed
    115. Gee AP. Regulatory issues in cellular therapies. J Cell Biochem Suppl. 2002; 38:104-12. PMID: 12046844.
      View in: PubMed
    116. Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4. PMID: 12473214.
      View in: PubMed
    117. Savoldo B, Goss J, Liu Z, Huls MH, Doster S, Gee AP, Brenner MK, Heslop HE, Rooney CM. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001 Sep 27; 72(6):1078-86. PMID: 11579304.
      View in: PubMed
    118. Gee A. Mesenchymal stem-cell therapy in a regulated environment. Cytotherapy. 2001; 3(5):397-8. PMID: 11953020.
      View in: PubMed
    119. Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75. PMID: 10910143.
      View in: PubMed
    120. Godder KT, Hazlett LJ, Abhyankar SH, Chiang KY, Christiansen NP, Bridges KD, Lee CG, Geier SS, Goon-Johnson KS, Gee AP, Pati AR, Parrish RS, Henslee-Downey PJ. Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. J Clin Oncol. 2000 May; 18(9):1856-66. PMID: 10784626.
      View in: PubMed
    121. Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, Körbling M, Huh YO, Geisler D, Gee AP, Champlin R, Przepiorka D. High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy. 2000; 2(2):105-10. PMID: 12042047.
      View in: PubMed
    122. Lamb LS, Abhyankar SA, Hazlett L, O'Neal W, Folk RS, Vogt S, Parrish RS, Bridges K, Henslee-Downey PJ, Gee AP. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease. Cytometry. 1999 Oct 15; 38(5):238-43. PMID: 10516610.
      View in: PubMed
    123. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24. PMID: 10706456.
      View in: PubMed
    124. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, Champlin RE, Körbling M. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion. 1999 Jun; 39(6):555-60. PMID: 10378833.
      View in: PubMed
    125. Gee AP. Are you feeling ablated? Cytotherapy. 1999; 1(4):269-70. PMID: 20426551.
      View in: PubMed
    126. Lamb LS, Gee AP, Hazlett LJ, Musk P, Parrish RS, O'Hanlon TP, Geier SS, Folk RS, Harris WG, McPherson K, Lee C, Henslee-Downey PJ. Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy. 1999; 1(1):7-19. PMID: 19746645.
      View in: PubMed
    127. Przepiorka D, Lu JG, Anderlini P, Körbling M, Donato M, Champlin R, Gee AP, van Vlasselaer P. Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system. Cytotherapy. 1999; 1(2):111-7. PMID: 19746587.
      View in: PubMed
    128. Gee AP. Product release assays. Cytotherapy. 1999; 1(6):485-91. PMID: 20426549.
      View in: PubMed
    129. Collins NH, Gee AP. ISHAGE committees--the whole is, indeed, and in deed, greater than the sum of its parts. Cytotherapy. 1999; 1(2):97-8. PMID: 19746585.
      View in: PubMed
    130. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24. PMID: 9704734.
      View in: PubMed
    131. Godder KT, Abhyankar SH, Lamb LS, Best RG, Geier SS, Pati AR, Gee AP, Henslee-Downey PJ. Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant. Bone Marrow Transplant. 1998 Jul; 22(1):111-3. PMID: 9678806.
      View in: PubMed
    132. Lamb LS, Gee AP, Henslee-Downey PJ, Geier SS, Hazlett L, Pati AR, Godder K, Abhyankar SA, Turner MW, Lee C, Harris WG, Parrish RS. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant. 1998 Mar; 21(5):461-71. PMID: 9535038.
      View in: PubMed
    133. Lamb LS, Robbins NF, Abhyankar S, Joyce M, Stetler-Stevenson M, Henslee-Downey PJ, Gee AP. Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad news. Bone Marrow Transplant. 1997 Jun; 19(11):1157-61. PMID: 9193762.
      View in: PubMed
    134. Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997 May 15; 89(10):3864-72. PMID: 9160695.
      View in: PubMed
    135. Ye Z, Gee AP, Bowers WE, Lamb LS, Turner MW, Henslee-Downey PJ. In vitro expansion and characterization of dendritic cells derived from human bone marrow CD34+ cells. Bone Marrow Transplant. 1996 Nov; 18(5):997-1008. PMID: 8932857.
      View in: PubMed
    136. Lamb LS, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, Gee AP. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996 Oct; 5(5):503-9. PMID: 8938522.
      View in: PubMed
    137. Civin CI, Trischmann T, Kadan NS, Davis J, Noga S, Cohen K, Duffy B, Groenewegen I, Wiley J, Law P, Hardwick A, Oldham F, Gee A. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol. 1996 Aug; 14(8):2224-33. PMID: 8708711.
      View in: PubMed
    138. Lamb LS, Gee AP, Parrish RS, Lee C, Walker M, Geier S, Harris G, Pati A, Godder K, Henslee-Downey PJ. Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: clinical and immunologic characteristics. Bone Marrow Transplant. 1996 Jun; 17(6):1021-7. PMID: 8807109.
      View in: PubMed
    139. Pati AR, Godder KT, Abhyankar SH, Gee AP, Henslee-Downey PJ. Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplant. 1996 Jun; 17(6):1081-3. PMID: 8807118.
      View in: PubMed
    140. Shpall EJ, Gee AP, Hogan C, Cagnoni P, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB. Bone marrow metastases. Hematol Oncol Clin North Am. 1996 Apr; 10(2):321-43. PMID: 8707758.
      View in: PubMed
    141. Godder K, Pati A, Abhyankar S, Gee AP, Parrish R, Lee C, Henslee-Downey PJ. Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT. Bone Marrow Transplant. 1996 Jan; 17(1):49-53. PMID: 8673054.
      View in: PubMed
    142. Laver J, Traycoff CM, Abdel-Mageed A, Gee A, Lee C, Turner C, Srour EF, Abboud M. Effects of CD34+ selection and T cell immunodepletion on cord blood hematopoietic progenitors: relevance to stem cell transplantation. Exp Hematol. 1995 Dec; 23(14):1492-6. PMID: 8542936.
      View in: PubMed
    143. Shpall EJ, Gee A, Cagnoni PJ, Hogan C, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB. Stem cell isolation. Curr Opin Hematol. 1995 Nov; 2(6):452-9. PMID: 9372035.
      View in: PubMed
    144. Gee AP. The corporate influence. J Hematother. 1995 Aug; 4(4):259-60. PMID: 7489139.
      View in: PubMed
    145. Pati AR, Godder K, Lamb L, Gee A, Henslee-Downey PJ. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 1995 Jun; 15(6):979-81. PMID: 7581101.
      View in: PubMed
    146. Collins N, Gee A, Rowley S, Shpall E. Are we ready for regulation? ISHAGE Regulatory Action Group. International Society for Hematotherapy and Graft Engineering. J Hematother. 1995 Feb; 4(1):1-2. PMID: 7757394.
      View in: PubMed
    147. Shpall EJ, Gehling U, Cagnoni P, Purdy M, Hami L, Gee AP. Isolation of CD34-positive hematopoietic progenitor cells. Immunomethods. 1994 Dec; 5(3):197-203. PMID: 7540099.
      View in: PubMed
    148. Gee AP. Immunologically based methods for the elimination of tumor cells from autologous stem cell grafts. Immunomethods. 1994 Dec; 5(3):232-42. PMID: 7780690.
      View in: PubMed
    149. Lamb L, Metherell J, Lee C, Brouillette M, Thompson J, Brown S, Henslee-Downey PJ, Gee A. Development of an immunomagnetic separation procedure to deplete V alpha beta-positive T cells from marrow for use in partially mismatched related donor (PMRD) transplantation. Prog Clin Biol Res. 1994; 389:541-50. PMID: 7700919.
      View in: PubMed
    150. Burgess J, Traycoff C, Hardwick A, Smith A, Hangoc G, Ishizawa L, Moubayed M, Broun R, Srour E, Gee A, et al. Separation of clinical quantities of CD34+ cells from human marrow using immunomagnetic procedures. Prog Clin Biol Res. 1994; 389:293-302. PMID: 7535434.
      View in: PubMed
    151. Lee C, Brouillette M, Lamb L, Pati A, Brown S, Thompson J, Parrish R, Henslee-Downey PJ, Gee AP. Use of a closed system for V alpha beta-positive T cell depletion of marrow for use in partially mismatched related donor (PMRD) transplantation. Prog Clin Biol Res. 1994; 389:523-32. PMID: 7700917.
      View in: PubMed
    152. Gee AP. Graft manipulation--a house of cards? J Hematother. 1994; 3(1):1-2. PMID: 7922003.
      View in: PubMed
    153. Gee AP. Preparation of samples for flow cytometric analysis. J Hematother. 1993; 2(3):413-9. PMID: 7522892.
      View in: PubMed
    154. Ishizawa L, Hangoc G, Van de Ven C, Cairo M, Burgess J, Mansour V, Gee A, Hardwick A, Traycoff C, Srour E, et al. Immunomagnetic separation of CD34+ cells from human bone marrow, cord blood, and mobilized peripheral blood. J Hematother. 1993; 2(3):333-8. PMID: 7522887.
      View in: PubMed
    155. Preti RA, Collins N, Gee AP. ISHAGE bone marrow processing survey: report on an international information gathering process. International Society for Hematotherapy Graft Engineering. J Hematother. 1993; 2(1):103-9. PMID: 7921961.
      View in: PubMed
    156. Gee AP, Collins NH. ISHAGE grows up. International Society for Hematotherapy and Graft Engineering. J Hematother. 1993; 2(1):1-2. PMID: 7921960.
      View in: PubMed
    157. Law P, Ishizawa L, van de Ven C, Burgess J, Hardwick A, Plunkett M, Gee AP, Cairo M. Immunomagnetic positive selection and colony culture of CD34+ cells from blood. J Hematother. 1993; 2(2):247-50. PMID: 7522881.
      View in: PubMed
    158. Cairo MS, Law P, van de Ven C, Plunkett JM, Williams D, Ishizawa L, Gee A. The in vitro effects of stem cell factor and PIXY321 on myeloid progenitor formation (CFU-GM) from immunomagnetic separated CD34+ cord blood. Pediatr Res. 1992 Sep; 32(3):277-81. PMID: 1383918.
      View in: PubMed
    159. Hardwick A, Law P, Mansour V, Kulcinski D, Ishizawa L, Gee A. Development of a large-scale immunomagnetic separation system for harvesting CD34-positive cells from bone marrow. Prog Clin Biol Res. 1992; 377:583-9. PMID: 1279728.
      View in: PubMed
    160. Hardwick RA, Kulcinski D, Mansour V, Ishizawa L, Law P, Gee AP. Design of large-scale separation systems for positive and negative immunomagnetic selection of cells using superparamagnetic microspheres. J Hematother. 1992; 1(4):379-86. PMID: 1345680.
      View in: PubMed
    161. Gee AP. Tumor cell purging and positive selection of hematopoietic stem cells. J Clin Apher. 1992; 7(3):135-7. PMID: 1363101.
      View in: PubMed
    162. Moss TJ, Xu ZJ, Mansour VH, Hardwick A, Kulcinski D, Ishizawa L, Law P, Gee A. Quantitation of tumor cell removal from bone marrow: a preclinical model. J Hematother. 1992; 1(1):65-73. PMID: 1365018.
      View in: PubMed
    163. Graham-Pole J, Gee A, Emerson S, Gallo J, Lee C, Luzins J, Janssen WE, Pick T, Worthington-White D, Elfenbein G, et al. Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood. 1991 Sep 15; 78(6):1607-14. PMID: 1884027.
      View in: PubMed
    164. Pole JG, Casper J, Elfenbein G, Gee A, Gross S, Janssen W, Koch P, Marcus R, Pick T, Shuster J, et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Jan; 9(1):152-8. PMID: 1985165.
      View in: PubMed
    165. Gee AP. Bone marrow purging and processing--a review of ancillary effects. Prog Clin Biol Res. 1990; 333:507-21. PMID: 2408064.
      View in: PubMed
    166. Pole JG, Gee A, Janssen W, Lee C, Gross S. Immunomagnetic purging of bone marrow: a model for negative cell selection. Am J Pediatr Hematol Oncol. 1990; 12(3):257-61. PMID: 2240471.
      View in: PubMed
    167. Janssen WE, Gee AP, Graham-Pole JR, Lee C, Luzins J, Spencer C, Worthington-White DA, Pick T, Koch P, Gross S. Transporting bone marrow for in vitro purging before autologous reinfusion. Prog Clin Biol Res. 1990; 333:541-9. PMID: 2309000.
      View in: PubMed
    168. Griebel PJ, Gee AP, Qualtiere L, Lawman MJ, Babiuk LA. Negative enrichment of bovine T lymphocytes with monoclonal antibodies and magnetic microspheres. Vet Immunol Immunopathol. 1989 Sep; 22(2):161-73. PMID: 2554562.
      View in: PubMed
    169. Gee AP, Mansour V, Weiler M. T-cell depletion of human bone marrow. J Immunogenet. 1989 Apr; 16(2):103-15. PMID: 2687381.
      View in: PubMed
    170. Saleh RA, Gross S, Cassano W, Gee A. Metastatic retinoblastoma successfully treated with immunomagnetic purged autologous bone marrow transplantation. Cancer. 1988 Dec 01; 62(11):2301-3. PMID: 3052786.
      View in: PubMed
    171. Ryffel B, Foxwell BM, Gee A, Greiner B, Woerly G, Mihatsch MJ. Cyclosporine--relationship of side effects to mode of action. Transplantation. 1988 Aug; 46(2 Suppl):90S-96S. PMID: 3043800.
      View in: PubMed
    172. Janssen WE, Munger KL, Gee AP. The migration of hematopoietic cells: an in vitro study system. Leukemia. 1988 May; 2(5):307-12. PMID: 3374168.
      View in: PubMed
    173. Gee AP, Boyle MD. Purging tumor cells from bone marrow by use of antibody and complement: a critical appraisal. J Natl Cancer Inst. 1988 Apr 06; 80(3):154-9. PMID: 3279217.
      View in: PubMed
    174. Graham-Pole J, Gee AP, Gross S, Casper J, Graham M, Harvey W, Kapoor N, Koch P, Mendenhall N, Norris D, et al. Bone marrow transplantation (BMT) for advanced neuroblastoma (NBL): a multicenter POG pilot study. Prog Clin Biol Res. 1988; 271:215-23. PMID: 3043449.
      View in: PubMed
    175. Kemshead JT, Treleaven J, Heath L, Meara AO, Gee A, Ugelstad J. Monoclonal antibodies and magnetic microspheres for the depletion of leukaemic cells from bone marrow harvested for autologous transplantation. Bone Marrow Transplant. 1987 Aug; 2(2):133-9. PMID: 3332162.
      View in: PubMed
    176. Gee AP, Lee C, Sleasman JW, Madden M, Ugelstad J, Barrett DJ. T lymphocyte depletion of human peripheral blood and bone marrow using monoclonal antibodies and magnetic microspheres. Bone Marrow Transplant. 1987 Aug; 2(2):155-63. PMID: 2901878.
      View in: PubMed
    177. Boyle MD, Chiodo VA, Lawman MJ, Gee AP, Young M. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol. 1987 Jul 01; 139(1):169-74. PMID: 2953811.
      View in: PubMed
    178. Boyle MD, Gee AP. Low antigen density tumor cells: an obstacle to effective autologous bone marrow purging? Cancer Invest. 1987; 5(2):113-8. PMID: 3300891.
      View in: PubMed
    179. Gee AP, Bruce KM, van Hilten J, Siden EJ, Braylan RC, Bauer PC, Boyle MD. Selective loss of expression of a tumor-associated antigen on a human leukemia cell line induced by treatment with monoclonal antibody and complement. J Natl Cancer Inst. 1987 Jan; 78(1):29-35. PMID: 3467127.
      View in: PubMed
    180. Boyle MD, Lawman MJ, Gee AP, Young M. Nerve growth factor: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol. 1985 Jan; 134(1):564-8. PMID: 3964821.
      View in: PubMed
    181. Boyle MD, Gee AP, Okada M, Borsos T. Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9. J Immunol. 1980 Dec; 125(6):2818-22. PMID: 7430645.
      View in: PubMed
    182. Gee AP, Boyle MD, Borsos T. Distinction between C8-mediated and C8/C9-mediated hemolysis on the basis of independent 86Rb and hemoglobin release. J Immunol. 1980 Apr; 124(4):1905-10. PMID: 7365242.
      View in: PubMed
    183. Boyle MD, Gee AP, Borsos T. Studies on the terminal stages of immune hemolysis. VI. Osmotic blockers of differing Stokes' radii detect complement-induced transmembrane channels of differing size. J Immunol. 1979 Jul; 123(1):77-82. PMID: 109541.
      View in: PubMed
    GEE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description